Invex Therapeutics (ASX:IXC) Net Income From Continuing Operations : A$0.11 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Invex Therapeutics's net income from continuing operations for the six months ended in Dec. 2024 was A$-0.36 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.11 Mil.

Invex Therapeutics Net Income From Continuing Operations Historical Data

The historical data trend for Invex Therapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Net Income From Continuing Operations Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Net Income From Continuing Operations

-3.36

-2.28

-3.95

-7.75

-1.64

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial						-3.85	-3.90	-2.11	0.47	-0.36

Invex Therapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.11 Mil.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.